

## Index

### **a**

acid deprotonation 10  
 acid-base catalysed ribozyme 11  
 activation barrier 7  
 activation entropy 5  
 activation free energy 4  
 active site guanine 108–109, 623  
 adenylate kinase (AK) 333  
 $\delta$ -agent 318  
 A756G ribozyme 62  
 aldol reaction 549, 595  
 aldolase ribozyme 547–548  
 alkylating ribozymes 545, 550–554  
 allosteric ribozymes 132, 293, 506–507,  
     513  
     rational design 511–512  
*Allovahlkampfia* LC ribozyme (AspLC)  
     866  
 amide-hydrolyzing deoxyribozyme 494  
 amino acids 29, 38–39, 93, 150, 174, 194,  
     199–200, 203–204, 209, 242, 244,  
     282, 285, 388, 393, 405, 435, 493,  
     512, 519–521, 523–527, 529–533,  
     537–538, 579–580, 589–590, 598,  
     601  
 aminoacyl-tRNA (aa-tRNA) 199–200,  
     202–205, 340, 519–520, 526–527,  
     530, 537–538, 722  
 aminoacyl-tRNA synthetases (ARSs)  
     340, 519, 520, 524, 526–527, 529,  
     722  
 aminoacylation ribozymes 519–538

aminoglycosides 255, 257, 259, 506, 870  
 aminoglycoside acetyltransferase (AAC)  
     259  
 2-aminopurine (2AP) 594, 625, 701–702  
 anti-HCV catalytic antisense 677  
 anti-HCV IRES 676, 678  
 anti-HIV-1 effect 671, 673  
 antigenomic polarity 29  
 antisense domain 666–674  
 antisense oligonucleotides (ASOs) 254,  
     267, 588  
 antiviral catalytic antisense 665–674  
 aptamers 287–288, 294, 366, 377,  
     402–403, 435, 491, 496, 505–508,  
     512, 547, 554, 574, 588, 593, 597,  
     602, 603, 628, 635, 672, 685–686,  
     688, 694, 703, 708, 721–733, 741  
     smaRt-SELEX 536–538  
 aptazymes 507, 512, 694, 696, 741  
     for gene regulation 512–514  
 hammerhead ribozymes (HHR) 507  
 ON- and OFF-switches mechanism  
     511  
 RNA classes 513  
 sequences 508, 510, 511  
 TPP-dependent hammerhead 513  
 apurinic endonuclease (APE) 31  
 arabino nucleic acids (ANA) 495, 496,  
     602  
 aromatic protons 7–8, 17  
 artificial DNA sequences 685  
 artificial riboswitches 506–507

- artificial ribozymes 435, 490–491, 494–495, 507, 520, 523, 524, 554, 573, 730–731
- A-site tRNA 196, 200–205, 208
- asymmetric rolling circle replication 28
- ATMND (2-amino-5,6,5-trimethyl-1, 8-naphthyridine) 702
- atomic mutagenesis 4, 12–13, 16, 78, 748
- ATP-aptazyme 696
- ATRib 520–524, 537
- A-type P RNA 234–235, 254
- autocatalysis 389, 420, 428–429
- autocatalytic Group II 173
- autocatalytic introns 663
- avocado sun blotch viroid* (ASBVd) 25–26, 37
- Avsunviroidae 25–27
- azidonorvaline (Any) 532, 533
- 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) 583, 694
- Azoarcus* RNA fragments 425–427, 429, 430
- Azoarcus* RNA genotypes 429–432
- Azoarcus* RNA self-assembly 425
- Azoarcus* group I intron 16–17, 351, 362, 420–422, 865
- Azoarcus* ribozymes 421–426, 428–430, 432, 433, 435
- CAU tag sequence 429
- genotypes 432
- IGS and tag 430
- self-assembly 426, 428, 431
- trans-esterification 423
- b**
- bacterial ribosome 195, 205, 255, 867
- Baggins retrotransposons 35
- bioactive peptides 532–535
- biocatalysis 282, 587
- bioinformatics 145, 286, 318, 365, 574, 869, 871
- biomacromolecules 3
- biorecognition element 708
- biosensing 577, 579, 599, 602, 651–652, 687, 688, 733
- biosensors 685, 686
- advantages 686
- mechanism 686–687
- N*-biotinoyl-*N'*-iodoacetyl-ethylenediamine (BIE) 550–551
- N*-biotinylated-Phe-AMP substrate 520
- bipartite binding 472
- blood-brain-barrier (BBB) 588
- Bohr magneton 818, 822
- Brønsted equation 13
- branch point adenosine (bpA) 763
- branch point sequence (BPS) 171–172, 179
- branched multiple hairpin (BMH) 672
- B-type ribozymes 233
- c**
- capping ribozymes 117–138, 340–346, 349, 491, 565–566, 866–868
- catalytic antisense RNAs
- DIS domains 672–674
- HCV IRES 674–677
- HIV-1 Poly(A) 672–674
- HIV-1 TAR 667–672
- in vitro* anti-HIV-1 673
- hypothesized mode 667
- catalytic beacons 697–699, 709
- catalytic domain (C-domain) 125, 148, 228–229, 444, 523–524, 669–670, 672, 677
- catalytic hairpin assembly (CHA) 699, 709–710
- reaction 710
- CAU tag 421–422, 424–425, 427, 429
- CCDC186 gene 315, 317
- cell level processes 402, 404–406
- cell sorting 136, 510
- cellular signal transduction 697
- central conserved region (CCR) 27, 28
- central dogma
- of molecular biology 193–194
- chemical reactions rate 3–5, 83, 91, 193, 194, 204, 366, 420, 651, 686, 721, 733, 861
- chemical shifts 7–8, 12, 14, 16–19

- chemically modified nucleotides 488  
 DNA and RNA catalysis 490–495  
 chloramphenicol acetyl transferase (CAT) 259, 261, 262, 762  
 4-chlorobenzyl thioester (CBT) 375–376, 379, 527–528  
 chloroplast-like (CL) 147  
 chromophores 623–628  
*chrysanthemum chlorotic mottle viroid* (CChMVd) 26  
 circRNA 303–304, 452–454  
 circular permutation 288, 464–466, 755, 767–770, 779  
 class I ligase 367, 372  
 selection 369  
 structure 370  
 coenzyme 3, 8, 18, 78–80, 82, 91–110, 281, 285–286, 402, 566  
 co-transcriptional cleavage ribozyme (CotC ribozyme) 323  
 colorimetric sensors  
 coupled with G4 DNAzyme 705, 707  
 gold nanoparticles 703, 704  
 hydrogel-assisted colorimetric detection 705, 706  
 label-free detection 703, 705  
 comparative modeling 862  
 compartmentalization  
 stochastic corrector model 399–401  
 surface metabolism 397–398  
 transient 397–398  
 compartmentalized bead tagging (CBT) 375–376, 379, 527, 528  
 5' conserved non-translated region (5'NTR) 667  
 cooperative self-assembly 429–430  
 CopT 666–667  
 core ribozyme 122, 331  
 coupling constant 818–822, 824, 841  
*CPEB3* gene 24, 41, 293, 319–322  
*CPEB3* ribozyme 320, 322, 489  
 C-terminal domain (CTD) 197, 233  
 C-type lectin-like family 2 (*CLEC2*) 307  
 cutaneous T-cell Lymphoma (CTCL) 312
- cyanomethyl ester (CME) 519, 521, 524, 528  
 cyclohexene nucleic acids (CeNA) 495–496  
 cytoplasm 128, 135–136, 254, 266, 320, 593
- d**
- decoding center (DC) 194–195, 201, 255  
 DeerAnalysis 826  
 delta antigen ( $\delta$ Ag) 29  
 denaturing gel electrophoresis 474, 479  
 deoxyribozymes (DNAzymes) 487, 492–494, 548, 557–558, 562–564, 566, 834  
 dephosphorylation reaction 580  
 DFHBI 731  
 DFT methods 821  
 Diels–Alder reactions 491, 583, 688, 843  
 Diels–Alderase ribozymes 546–547, 726, 727  
 electron paramagnetic resonance spectroscopy 843, 845  
 dimerization initiation site (DIS) 668, 672–674  
 dimethyl sulfate 467  
 dinitro-flexizyme (dFx) 527  
 direct tRNA aminoacylation 523–526  
 DirLCrz  
 spliceosomal intron I51 in 131  
 structure of 123, 125–128  
 discontinuous hammerhead ribozyme (dis-HHR) 307–308, 310  
 divalent cations 71–72, 75, 100, 368, 767, 773, 800, 862, 870  
 dN<sup>\*</sup>TPs 574, 588, 595, 597, 601–603  
 DNA amplification approach 728  
 DNA enzymes  
 catalytic repertoire 574–587  
 hydrolytic reactions 575–580  
 ligase and other activities 580–584  
 post-SELEX modification 589–595  
 practical applications 588–589  
 SELEX polymerization 595–602

- DNA enzymes (*contd.*)  
 structural and mechanistic considerations 584–587  
 DNA intermediate 29–30  
 DNA polymerization 352  
 DNA strand 33, 332, 377, 578–579, 623, 626–629, 647, 651, 705, 759, 834, 838  
 DNA-functionalized gold nanoparticles 703  
 DNA-splint 557, 789, 832–834  
 DNAzymes 548–550, 635, 638, 640  
   ANDAND gates 636, 637  
   ANDANDNOT gates 637  
   aptazymes 694–696  
   beacon sensor 698  
   biochemical characterizations of 696  
   cancer therapy 651  
   cascades 650, 651  
   catalytic core 635, 636  
   catalytic properties 590  
   chemical mechanisms 586  
   cleavage reactions 635, 636, 640, 650  
   colorimetric sensors 702–707  
   coupled with G4 705, 707  
   disadvantages 686  
   dN\*TPs 597  
   E6 motif 635, 636  
   electrochemical sensors 707–708  
   fluorescent sensors 697–702  
   hydrolyzing DNA phosphodiester linkages 578, 580  
   for lanthanides and actinides 690–692  
   ligases 651  
   linear substrates 635, 636  
   logic gates 638  
   MAYA-I 637, 643  
   MAYA-II 638, 643  
   MAYA-III 639  
   metal sensing 694  
   molecular automata 637  
   molecular beacons 635  
   8-17 motif 642  
   Na<sup>+</sup> 693  
   NOT gates 636, 637  
   OR gates (implicit) 637  
 parallel gate arrays 637  
 for Pb<sup>2+</sup> 688–690  
 pharmacokinetic properties 590, 593  
 with phosphatase activity 581  
 phosphodiesterases 635  
 for physiologically abundant metals 692–694  
 post-SELEX modification 593, 595  
 RNA-cleaving 575, 578  
 RNA-ligating 585  
 secondary structures 576  
 sensors coupled with signal amplification mechanisms 708–711  
 structured substrates 640  
 substrate binding arms 635  
 for thiophilic metals 690, 692  
 YES gates 635, 636  
 Zn<sup>2+</sup> 691  
 domain 7 (D7) 153  
 double-strand break repair (DSBR) 150  
 double-stranded DNA (dsDNA) 149–150, 559, 623, 647, 705  
 3D reference site interaction model (3D-RISM) 869–870  
 droplet fusion device 730  
 droplet microfluidic screening strategy 732  
 3D structure, ribozymes  
   modeling approach combination 867  
   RNA interactions with ligands 867–868  
   template-based modeling 862, 865–866  
   template-free modeling 866–867  
 DTNB gene 316  
 dystrobrevin beta protein (DTNB) 315
- e**
- 17E 690, 697, 702–704, 709–710  
*E. coli* ribosome 194, 530  
 EDNMR 821  
 EF-Tu (elongation factor thermo-unstable) 198–202, 206, 211  
 Egr-1 factor binds 576  
 EGS technology

- in eukaryotic cells 259–261  
 M1-GS approach 265–266  
 nuclear-cytoplasmic RNase P 260–265  
 oligonucleotides 259, 261–265  
 $\text{EGS}^{\text{CAT}}$  261–262  
 electrochemical sensors 707, 708  
 electron nuclear double resonance (ENDOR) 821, 839, 841  
 electron paramagnetic resonance (EPR) spectroscopy  
     Diels Alder ribozymes 843–845  
     group I intron 845  
     hammerhead ribozymes 838–843  
     magnetic interactions 818–820  
     multifrequency continuous wave (cw) 820–821  
     non-ribozyme RNAs 847, 849  
     pulsed EPR dipolar spectroscopy 821–828  
     pulsed hyperfine spectroscopy 821  
     ribosome 845–847  
     site directed spin labeling 828–838  
 electron spin echo envelope modulation (ESEEM) 821, 839, 841  
 electron spin resonance (ESR) spectroscopy 817  
 electron–electron double resonance (ELDOR) 821, 824  
 electrophilic catalyst 687  
 electrostatic stabilization 8, 16, 64, 105  
 elongation  
     decoding 200–202  
     peptide bond formation 202–205  
     translocation 205–208  
 elongation factor G (EF-G) 196, 200, 233  
 endonuclease (En) domains 30, 31, 36, 145, 148–150, 154, 179  
 endonucleolytic ribozymes 754, 755, 773  
 enzymatic RNA polymerization 361–363, 366, 371  
 enzyme-linked immunosorbent assay (ELISA) 707, 708  
 enzyme-substrate (E-S) complexes 242, 247, 249, 251, 257, 423  
 error thresholds 364, 391, 393, 396  
     neutrality of mutations 393, 406  
     exogenous guanosine (exoG) 130, 761  
     exon binding sites (EBS) 145, 764  
     exonuclease-mediated degradation 25  
     expressed sequence tag (EST) 310–312, 317–318
- f**
- FARFAR 866  
 flavin mononucleotide (FMN) 18, 92, 339, 445–447, 454, 507, 566  
 flexible in vitro translation (FIT) system 529, 532, 537  
 flexizyme ribozymes 523–526  
 flexizymes  
     and activating groups 528  
     to genetic code reprogramming 527–530  
 fluorescence polarization/anisotropy (FP/FA) assay 257  
 fluorescence resonance energy transfer (FRET) 98, 442, 470, 557, 584, 587, 765, 817, 847  
 fluorescence spectroscopy 158, 564, 633, 777  
 fluorescent nucleobases 701  
 fluorescent sensors  
     catalytic beacons 697–699  
     folding detection 701–702  
     internally labeled DNAzymes 699, 701  
     intracellular sensing 699, 700  
 2'-fluoroarabino nucleic acids (FANA) 495–496, 602  
 fluorogenic substrate 727, 732  
 fluorophore-quencher system 577, 635  
 fluorophore/quencher pair 699, 701  
 folding detection 701–702  
 formyl-methyl-transferase (FMT) 198  
 Friedel–Crafts reaction 548–550, 583
- g**
- game theoretic treatment 430–432  
     significance 432–433  
 genes encoding 227, 289, 726  
 genetic code reprogramming 520, 527–530, 538

- genetic variability 665  
 genotype-phenotype link 722, 723,  
   725–726  
 GIR1 119  
 GIR2 119  
*glmS* riboswitch 93, 758  
*glmS* ribozyme 41, 42, 78–80, 287, 756  
   active site guanine 108–109  
   biochemical analyses 95–98  
   biological function of 94–95  
   coenzyme dependence 101–102  
   crystallographic analyses 98–99  
   GlcN6P 102–104, 106  
   mechanism of 104–109  
   metal ions 99–101  
   pH-reactivity profiles 106–108  
   riboswitch function 109–110  
   secondary structure 96  
*glmS* RNA 94, 97–102, 104, 106,  
   286–288, 757  
 β-globin 323  
 glucosamine-6-phosphate (Glc6P) 41,  
   78–80, 99, 102, 757  
 glucosamine-6-phosphate (GlcN6P)  
   41–42, 92–101, 104–109, 286–287,  
   757–758  
   functional groups 102–104  
 glutamine-recognition domain 521  
 glycine riboswitch 832, 834  
 glycosidic bond forming ribozymes 332,  
   336–340  
 gold nanoparticles (AuNPs) 592–593,  
   697, 703, 705  
 G-quadruplex DNAzyme 695  
 green fluorescent protein (GFP)  
   135–136, 448, 509, 510, 731  
 group I introns 421  
   case studies 869  
   electron paramagnetic resonance  
    spectroscopy 845  
   2'-hydroxyl group 761–763  
   nuclear magnetic resonance 804–805  
   splicing pathway mediated 762  
 group I intron splicing ribozymes (GrIrz)  
   117  
   into LCrz 133  
 group I ribozyme switching 128–130  
 group II introns (GIIi) 170, 187  
   active site 154–156  
   biotechnological applications 157–158  
   characterization of 143–145  
   classification 147  
   conservation and biological role  
    145–152  
   differentiation 148–149  
   evolutionarily-acquired properties  
    148–149  
   folding 153–154  
   2'-hydroxyl group 763, 765  
   intron encoded-protein 154  
   long-range tertiary interactions  
    152–153  
   non coding RNAs 157  
   nuclear magnetic resonance 806  
   phylogenetic classification 145–148  
   reaction mechanism 154–156  
   retrohoming pathways 150, 152  
   retrotransposition pathways 152  
   secondary and tertiary structures 146  
   secondary structure 152–153  
   self-splicing of 763  
   splicing machineries 156–157  
   spreading 149–150  
   stabilization by solvent 154  
   structure of 764  
   sub-megadalton enzymes 145  
   survival 149–150  
 GTPγS 333, 335  
 guanosine monophosphorothioate  
   (GMPS) 551  
 guanosine-5'-triphosphate (GTP) 92,  
   194, 197–202, 206, 211–212, 331,  
   346, 365–366, 371, 373, 377, 563,  
   564, 566, 601  
 guanosine-33 747  
 guanosine-40 743, 744  
 guanylate kinases (GUKs) 333  
 guide sequence (GS) concept 125,  
   258–259, 265, 421–427, 429–431,  
   433, 521–522, 845

***h***

- hairpin ribozymes 61, 65, 66, 463, 766  
 case studies 868  
 external oligonucleotide effectors 444  
 FMN 447  
 $2'$ -hydroxyl group 765, 767  
 mediated recombination 451  
 mediated RNA circularization 453  
 mediated self-splicing 455  
 nuclear magnetic resonance 801  
 regulated by external effectors 443–446  
 RNA recombinases 449–451  
 self-splicing 452–454  
 structural variants of 442–443  
 structure and mechanism 439–441  
 twin ribozymes 446–449
- hammerhead ribozyme (HHR/HHRz) 304, 305, 307  
 case studies 870  
 electron paramagnetic resonance spectroscopy 838–843  
 folding of 843  
 $2'$ -hydroxyl group 69, 71, 759, 761  
 $Mn^{2+}$ -binding site 839, 841  
 nuclear magnetic resonance 800–801  
*Penelope*-like elements 35, 39  
*Schistosoma mansoni* 39–40  
 and pistol 71  
 plant retrotransposons 40  
 PLEs' mode 37  
 structure of 70  
 hatchet ribozymes 57, 82, 92, 291  
 HDV ribozyme (HDVP) 14, 756  
 for retrotransposition 30–34  
 other non-LTR retrotransposon lineages 34–35  
 HEG P1 129–130  
 HeLa cells 511  
 helix shift 467, 470–472  
 helix slippage mechanism 507  
 helix-length compensation 474–475  
 hepatitis  $\delta$  virus (HDV) RNA 29  
 direct role 72–74  
 nuclear magnetic resonance 794–799  
 ribozymes 57, 73  
 ribozyme, case studies 870  
 and TS ribozymes 74–76  
 Hepatitis D virus (HDV) ribozymes 303, 318–320  
 hexaquo-magnesium ions 14  
 hexitol nucleic acids (HNA) 495–496, 602  
 HH9 ribozyme 310  
 histidine 10, 13, 17, 59, 393, 492, 598  
 HIV-1 Poly(A) 672–674  
 HIV-1 TAR 476, 479, 481, 667–672  
 homing endonuclease (HE) 117–120, 128–131, 133, 136, 294  
 homing process 145  
 homolog of *Aquifex* RNase P (HARP) 227, 228  
 homology modeling 862  
 horseradish peroxidase (HRP) 651, 707–708  
 HVI-1 5'NTR 668  
 hybridization chain reaction (HCR) 710  
 hydrated metal ion 8, 15, 18, 59, 72–73, 75–76, 78, 80–82  
 hydrogel-assisted colorimetric detection 705  
 hydrogen bonding 4, 8, 64, 67, 74, 101–102, 105, 108, 210, 241, 361, 370, 373, 434, 496, 511, 584, 744, 747–748, 776, 832, 870  
 hydrolysis reaction 124, 132, 174  
 hydrolytic reactions 5, 575–580  
 $2'$ -hydroxyl group  
 group I intron 761–763  
 group II intron 763–765  
 hairpin ribozyme 765–767  
 hammerhead ribozyme 759–761  
 hyperfine sublevel correlation experiment (HYSCORE) 821, 841, 842  
 hyperfine-coupling 818–821, 841

***i***

- IBS3 147, 153  
 IIA1 148

- imino protons 92, 471, 791, 796–799, 804–805  
 imino walk 8  
*in situ* hybridization 135  
*in vitro* compartmentalization (IVC)  
 double emulsions 728  
 emulsion-free 729–730  
 gene modification 726–727  
 microbead-display 728–729  
 microfluidic-assisted 730, 731  
 modified genes 723  
 ribozyme discovery 725–730  
 ribozymes isolation 727  
 screening catalyst-coding gene 727–728  
*in vitro* selection 23  
 artificial ribozymes 494–495  
 chemically modified nucleotides 490–491  
 deoxyribozyme pool 493  
 deoxyribozymes with modified nucleotides 492–494  
 methods 507–511  
 unnatural nucleotides 491–492  
 XNAzymes 495  
*in vitro* transcription 124, 134, 315, 488–489, 492, 494, 557, 634, 726, 729, 730, 732, 759, 777, 779, 787–788  
*in vivo* screening methods 508–511  
 infrabiological systems 390–391  
 initiator-tRNA ( $tRNA_i$ ) 196–199  
 INT 14  
 internal guide sequence (IGS) 125, 422–424, 429–432, 521–523, 845  
 internal ribosome entry site (IRES) 31, 35, 136, 255, 292, 674–678, 834  
 internal stem loop (ISL) 171, 176, 177, 182, 187, 445  
 internally labeled DNAzymes 699, 701  
 intracellular sensing 686, 699–700  
 intramolecular RNA–RNA interactions 665  
 intron binding sites (IBS) 145–147  
 intron encoded-protein (IEP) 117, 145, 154  
 intron lariat spliceosome (ILS) complex 172, 185  
 intronic HDV-like ribozyme 320–322  
 intronic HH9 hammerhead ribozymes 311  
 intronic HHR 310–318, 320, 322  
 introns and splicing 169–170  
 inverse electron demand Diels–Alder cycloaddition (iEDDA) 834  
 iridium hexammine 776  
 isomerization step 249  
 isothermal titration calorimetry (ITC) 470  
 isotope-labeled RNAs 3  
 isotopic labeling 10  
 isotopically labeled RNA 10  
 isotropic 818–820, 822, 841  
 $\mu$ IVC 730–731, 733  
 light-up RNA aptamers 731  
 I/V kissing-loop interaction 466–468
- k**  
 keto-enol tautomerization 202  
 kinase ribozymes 332–337  
 kissing-loop complexes 470–471  
 kissing-loop interaction (KLI) 290, 464, 466–468, 477, 665–669  
 kissing-loop substitution 475–476
- l**  
 label-free detection 702–703, 705  
 labeling long RNAs 832–834  
 lanthanides 563, 579, 690, 753, 765  
 lariat cap (LC) 130, 134–136  
 formation 117  
 lariat capping ribozyme (LCrz) 117, 768, 769  
 basics 117–119  
 branching reaction 118, 122, 123  
 case studies 868  
*DirLCrz* 125–128  
*DirLCrz vs. NaeLCrz* 121

- DirLCrz vs. AspLCrz* 121  
discovery 119  
group I ribozyme switching 128, 130  
LC ribozyme switching 130–131  
ligation and hydrolysis 122, 124  
model 132  
*Naegleria* type 126, 128  
nomenclature 120  
reaction conditions 124  
research tool 134–136  
species involved 120–121  
spliceosomal intron I51 131  
spliceosomal splicing 132, 134  
switching 130–131
- leadzyme**  
nuclear magnetic resonance 802–803
- ligand binding shifts** 847
- ligand docking**  
case studies 870–871
- ligase ribozymes** 332, 343–351, 362, 366, 368, 389, 402, 424, 428, 554, 565, 722, 724–725, 728, 798
- locked nucleic acid (LNA)** 254, 259, 266, 487, 489–490, 591, 595
- logic**  
adder circuits 637  
disjunctive normal form 637
- long distance interaction (LDI)** 672
- long terminal repeats (LTRs)** 30, 31, 35–40
- L-RNA substrates** 578
- L1Tc** 35–36
- m**
- magnesium ions** 14, 243, 434, 442, 450, 464, 467, 744, 760, 765, 767, 774, 776–777, 792, 871
- magnetic interactions** 818–820
- MaN6P** 99
- mCSP** 262
- messenger RNA (mRNA)** 92, 169, 193, 308, 340, 405, 421, 445, 490, 505, 667, 763
- biogenesis** 41
- pre-mRNAs** 169–174
- metal ions** 838  
hypothesis 175  
monovalent 100  
two-metal ion mechanism 247–250
- 6-methyl isoxanthopterin (6MI)** 584, 623, 627
- M1-GS approach** 265–266
- Michael reaction** 551–552
- microbead displays** 376, 728–730
- microfluidic-assisted** 730–732  
μIVC 730–731  
light-up RNA aptamers 731
- microhomology** 34
- mitochondrial-like (ML)** 147
- Mn<sup>2+</sup>-binding site** 839–842, 845–846
- modeling approach combination** 867
- monovalent metal ions** 70, 78, 100–101, 594
- multifrequency continuous wave (cw) EPR** 820, 821
- murine cytomegalovirus (MCMV)** 262, 266
- mutant flexizymes** 530–532
- n**
- NaA43 DNAzyme** 692, 693, 695, 700
- Naegleria* type LCrz** 126–128, 130, 131
- nanoclusters** 629
- nascent polypeptide chain (NC)** 194
- natural ribozymes** 3, 5, 117  
acidic-basic aspects of  
transesterification 770–773
- chemical modifications** 489–490
- circular permutation** 767–770
- hammerhead and hairpin** 664
- 2'-hydroxyl group** 759–767
- location of cleavage site** 755, 757  
mechanistic and structural studies  
488–489
- pistol ribozyme** 777
- strategies to inactivate nucleophile** 754–755
- transesterification reaction** 768

- natural ribozymes (*contd.*)
- twister ribozyme 773–775
  - twister sister (TS) ribozyme 776–777
- ncRNAs 193, 285, 288, 290, 295–296
- NDP 343
- neural networks
- artificial 639
- Neurospora* Varkud Satellite RNAs
- 29–30
- Neurospora* Varkud satellite (VS)
- ribozyme 463, 464
- S/R complex 473–474
- circular permutations and *trans*
- cleavage 464–466
- crystal structures of dimeric form 473
- divide-and-conquer strategy 471
- engineering 480–481
- helix-length compensation 474–475
- I/V kissing-loop interaction 466–468
- improving cleavage activity 478–480
- kissing-loop complexes 470–471
- kissing-loop substitution 475–476
- nuclear magnetic resonance 802
- SLI 466–468
- SLI sequences 468–470
- N-glycanase 1 (NGLY1) gene 315
- NHS-ester chemistry 489
- nitroxides 818, 820, 822, 824, 826, 828, 832, 834, 837–838, 847
- NMP 343
- NOESY 8–10, 12–13, 16–22
- non-bridging oxygen 5, 64, 80, 176, 244, 248, 584, 597, 687, 692, 743–744, 746–748, 774
- non-coding RNA (ncRNA) 143, 157, 193, 266, 285–286, 288–291, 294–296
- non-covalent labeling 834, 837
- non-enzymatic polymerization 361
- non-enzymatic RNA polymerization 360–361
- non-LTR retrotransposons
- HDV-like ribozymes for retrotransposition 30–34
- lineages 34–35
- non-natural nucleotides 487–489, 491, 494, 834
- non-proteinogenic aminoacyl-tRNAs
- (nPAAs) 520
- non-ribozyme RNAs
- oligonucleotide-protein complexes 847, 849
  - riboswitches 847, 848
- non-Watson-Crick pair 429–430
- nPAAs 520, 527, 530, 532–535, 537–538
- ortho*-nitrophenyl ethyl (NPE) 6
- N-terminal domain (NTD) 197
- NTP 343, 351–352, 372–374, 377–378, 399, 565, 598, 787, 794
- nuclear localization signal (NLS) 29, 39
- nuclear magnetic resonance (NMR)
- spectroscopy 785–789
- group I introns 804–805
- group II introns 805
- hairpin ribozyme 801
- hammerhead ribozyme 800–801
- hepatitis delta virus 794–799
- isothermal titration calorimetry 470
- kissing-loop complexes 470–471
- labeling of particular RNA regions 789–790
- leadzyme 802–803
- Neurospora* Varkud Satellite ribozyme 802
- photocaging strategy 790
- resonance assignment 792–794
- Ribonuclease P 803–804
- RNA initial screening 791–792
- nuclear-cytoplasmic RNase P 227, 254, 255, 260–265
- nucleic acids
- catalytic 635
  - complementary 635–637
  - oligonucleotides 636
- nucleobases 12, 463
- adenine and guanine 9–13
  - nucleolytic ribozymes 8–9
  - pKa values 10, 18
  - substitution 12

- nucleolytic ribozymes 5, 6, 57, 58  
acid-base catalysis 59, 60  
acids and bases reactivity 13  
active catalyst fraction 9–13  
chemical mechanism 7, 58  
classification 80–83  
*glmS* 78–80  
hairpin and VS 61–66  
hammerhead 69–71  
hepatitis delta virus 72–74  
pH dependence of reaction rates 9–13  
pistol 76–78  
pKa shifting 13–14  
secondary structures 58–60  
twister 66–69  
twister sister (TS) 74–76  
nucleolytic RNAs 741, 753  
nucleophile deprotonation 8  
nucleophilic attack 5, 7, 8, 17, 67, 70,  
76, 79, 101, 104, 108, 117–118,  
122, 185, 201–204, 335, 345, 346,  
347, 361, 368, 370–371, 373, 422,  
440, 550, 553, 687, 744, 754, 763,  
768  
nucleoside monophosphate kinases  
(NMPKs) 332–333  
nucleosides 591  
phosphoramidite 5  
triposphates 332–333, 335, 372–373,  
403, 488, 491–492, 595, 597–602  
nucleotide analog interference mapping  
(NAIM) 64, 95–98, 109, 251, 488  
nucleotide analog interference  
suppression (NAIS) 95, 97  
2-nucleotide-bulge 153  
nucleotide kinases (NKS) 332
- O**
- oligomeric transcript 26–28  
oligonucleotides 5, 575  
antisense 254, 266, 588  
protein complexes 847  
RNA 759  
synthetic 768
- open reading frame (ORF) 29, 31, 34–36,  
38, 93, 130–131, 145, 148, 153, 188,  
287, 289, 292–294, 308, 463, 532,  
675  
orthogonal tRNA/ribosome pair 533
- p**
- Pake pattern 824  
Pb<sup>2+</sup> sensor 704  
*peach latent mosaic viroid* (PLMVd) 26  
*Penelope*-like elements (PLEs) 30, 40,  
307  
hammerhead ribozymes 35–39  
*Penelope*-like LTRs (PLTRs) 30, 37  
penelope-like retrotransposable elements  
(PLEs) 307  
peptide bond formation 91, 195–197,  
200, 202–206, 210–211, 284–285,  
331, 359  
peptidoglycan 286  
peptidyl transfer catalyst 521  
peptidyl transferase center (PTC)  
194–195, 202–205, 209–211, 359,  
435  
pH-reactivity profiles 106–108  
phenothiazine derivatives 255, 257  
phosphodiester 744, 746, 748  
bond 440  
transesterification 754  
phosphor-ester linkage 420  
phosphoramidite 557, 574, 590, 597, 789,  
828–829, 832  
phosphorane 5, 7–8, 58, 64–65, 687, 690,  
754, 767, 772  
phosphorothioate (PS) 175, 692, 817, 829  
method 16  
modification 73  
5-phosphoribosyl 1(α)-pyrophosphate  
(PRPP) 332, 336–340, 404  
phosphoryl transfer catalysis 6–8  
phosphoryl transfer enzymes 331, 332  
capping ribozymes 340–344  
glycosidic bond forming ribozymes  
336–340

- phosphoryl transfer enzymes (*contd.*)
- kinase ribozymes 332–336
  - ligase ribozymes 344–350
  - polymerase ribozymes 351–353
  - phosphoryl transfer reactions 3–7, 16–18, 173, 176, 248, 331–333, 337, 340, 353
  - phosphoryl transferase 336
  - phosphorylation 331–336, 349, 351–352, 403, 566, 688
  - photo-cross-linking assays 587
  - photoactive DNA components 625–629
  - photocaging groups 596
  - photocatalysts 624–625
  - photochemical DNAzyme (PDZ) 621
    - design 627
    - photoactive DNA components 625–629
  - photoDNAzymes (PDZs) 622–624
  - photoenzymes 621–622
  - photolabile caging group 6
  - photolyases 583, 593, 621–623, 625–626, 629
  - phylogenetic classification 145–148
  - picoinjector 730
  - pistol ribozymes 71, 76–78, 291, 742
    - env25 743, 745
    - guanosine-33 747
    - guanosine-40 743–744
    - mechanistic proposal 747–749
    - natural ribozymes 777
    - purine nucleoside-32 744–747
    - structural aspects of 778
    - structures of 741–743
  - p*K<sub>a</sub>* shifting 13–14
  - Planck constant 822
  - poly-purine tract (PPT) 36, 40
  - polyacrylamide chains 705
  - polyethylene glycols (PEG) 592–593, 595, 726, 753
  - polymerase chain reaction (PCR) 261, 377, 552, 574, 692, 710, 722
  - polymerase III promotor 39
  - polymerase ribozymes 332, 350–353, 359–381, 390, 395–396, 433, 435, 565, 727, 733
  - polynucleotide nucleotide kinase (PNK) 332–333
  - polyphosphorylating reagents 335
  - Pospiviroidae 25–28
  - post-SELEX modification 589–595
  - postsynthetic labeling 829–832
  - potato spindle tuber viroid* (PSTVd) 25
  - ppRNA 343, 344, 349
  - pre-rRNA processing 128, 130
  - pre-spliceosome
    - A complex 179
    - activated B complex 182–183
    - B complex 179–182
    - C and C\* complex 183–185
    - intron lariat spliceosome (ILS) complex 185–187
    - P complex 185
    - tri-snRNP 177–179
  - precursor tRNA (pre-tRNA) 234, 248, 260
  - precursor-messenger RNAs (pre-mRNAs) 169
    - introns 172
    - splicing 170, 171, 173, 174, 189
  - prenyltransferases 548
  - primer binding site (PBS) 36, 40, 377, 550, 668, 672
  - primer extension (PEX) 119, 124, 360, 367, 371, 379, 565, 574
  - proteins
    - catalyzed phosphoryl transfer 248
    - enzymes 173, 519, 589
    - signaling cascades 650
  - proteinogenic amino acids (PAAs) 519, 527, 530
  - protonation 7–9, 12–13, 59, 61–62, 66, 68, 102–104, 109, 744, 746–747, 796, 801
  - pseudo-atoms 866
  - pseudoknots 28, 31, 33, 58–59, 66–67, 72, 75–77, 79, 95, 99, 125–126, 128, 132–133, 234–235, 287–289, 292, 296, 523, 550, 587, 741–742, 757, 773, 777, 796–797
  - pseudo-photoDNAzymes 624–625

- pulsed electron-electron double resonance (PELDOR) 824–827, 829, 832, 834, 837, 843, 846–847, 849–850
- pulsed EPR dipolar spectroscopy (PDS) 821–828
- data conversion into distance distributions 824, 826
  - distance distributions into structures 826, 828
  - experiments 824
- pulsed hyperfine spectroscopy 821, 823, 838
- purine nucleoside-32 744, 747
- pyridyl modified nucleobases 494
- q**
- quadrupole coupling 820, 841
- quantitative polymerase chain reaction (QPCR) 710
- quantum mechanical/molecular mechanical (QM/MM) 71, 100, 105, 108
- quasi species model 392
- r**
- RAGATHs (RNAs Associated with Genes Associated with Twister and Hammerhead) 290–291
- Raman crystallography 64, 106
- RaPID 532–535, 538
- ratcheting 206–207
- rate-limiting step 98, 197, 203, 249, 368, 371, 665, 804
- rDNA transcription 130
- real-time NMR (RT-NMR) 790
- recombinase ribozymes 420–421, 433–434
- relaxation induced dipolar modulation enhancement (RIDME) 824, 837
- release factor 1 (RF1) 208
- R2 endonuclease 33
- replicase ribozymes 396–397, 399, 401
- residual dipolar coupling (RDC) 16, 19–20
- residues, mutation of 770–773
- resonance assignment
- selective labeling 794
  - uniform labeling 794
- retroelements 34, 37–38, 149, 158, 162, 292–293, 303–304, 312, 318
- retrohoming 145, 148–150, 152
- retrotransposition 25, 30–34, 145, 148, 150, 152, 154, 156, 158, 303–304
- retrotransposon 30–36, 38–40, 303–305, 307, 320, 323
- retrotransposon-like elements (RTEs) 35
- retrozyme life cycle 40
- retrozymes 28, 30, 36, 40, 304–305, 307
- reverse splicing pathway 763
- reverse transcriptase (RT) 29, 30, 33, 36, 174, 377, 419, 722, 763
- domain 31, 37, 145, 150, 332
- Reversion-inducing Cysteine-rich protein with Kazal motifs (RECK) 310–313, 315, 317–318
- ribocells
- cell level processes 404–406
  - compartmentalization 396–401
  - error thresholds 406
  - genetic information,–389
  - hypothetical minimal metabolism for 404
  - intermediate metabolism 402–403
  - metabolic complexity 389–391
  - minimal organism 401–402
  - stages of 387–388
- ribonuclease P 72, 282, 721, 753
- nuclear magnetic resonance 803–804
- ribonucleoprotein (RNP) 145, 170, 229, 282–284, 435–436, 520, 721
- ribonucleoprotein particle (RNP) 170
- ribonucleoside-triphosphates (rNTPs) 3
- β-D-ribopyranose 336
- ribose modifications 487, 490
- ribosomal DNA (rDNA) 30
- ribosomal proteins (rProteins) 194–195, 197–198, 284, 393
- ribosomal RNA (rRNA) 120, 169, 193, 284, 331, 421, 481, 512, 591
- ribosome
- bacterial ribosome 195, 205, 255, 867

- ribosome (*contd.*)
  - electron paramagnetic resonance spectroscopy 845–847
- riboswitch function 93, 95, 109, 110
- riboswitches 92, 93, 285, 753
  - conditional gene expression control 505–506
  - engineered 506–507
  - non-ribozyme RNAs 847
- ribozyme classes 23–25, 42–43, 282, 288, 290, 292, 294, 748, 785, 862, 863
- ribozymes 3, 4, 91, 92, 289–291
  - acid-base catalysis 17–18
  - domesticated 292–294
  - guanine and adenine 62
  - hairpin or twister 16
  - metal ions role 14–17
  - ncRNAs 295–296
  - new catalytic RNAs 294
  - phosphoryl transfer reactions 5–6
  - protein advantages 282–283
  - protein takeover 282
  - RNA searches 285–289
  - serendipity 283–285
  - use of metal ions 17–18
- ribozymes catalyzing
  - acyl transfer to RNAs 520–521
  - direct tRNA aminoacylation 523–526
  - tRNA aminoacylation via self-acylated intermediates 521–523
- ribozymes crystallization 755
- RNA catalysis
  - chemical reactions rate 4–5
  - limitations to 18
  - nucleolytic ribozymes 8–13
  - $pK_a$  shifting 13–14
  - phosphoryl transfer 6–8
  - phosphoryl transfer reactions 5–6
  - ribozymes 3, 4
  - transition state theory 4–5
- RNA catalysts 91, 93, 97–98, 281–283, 290, 331, 339–340, 448, 492, 545, 548, 550, 559, 566
- RNA degradation 150, 259, 367, 372, 743
- RNA enzymes 285, 337, 349, 387, 519
- RNA interactions with ligands 867–868
- RNA intermediate 28–31, 33, 38, 304
- RNA labeling, spin labels for 830
- RNA labeling methods 4
- RNA ligation 332, 345, 365, 368, 380, 419, 420, 557–567, 651
- RNA molecules 40, 91, 121, 134, 138, 157, 193, 194, 255, 312, 332, 344, 346, 349, 389, 391, 419, 433, 434, 448, 450, 482, 546, 552, 558, 565, 573, 574, 663, 665, 670, 671, 675, 677, 722, 861, 862, 867, 871
- RNA oligomers 28, 332, 333, 336, 341, 421, 433, 435, 520
- RNA oligonucleotides 360, 362, 367, 372, 380, 557, 574, 589, 759
- RNA polymerase (RNAP) II 135
- RNA polymerase ribozymes (RPR) 360, 367, 372, 373, 375
  - selecting improved polymerase activity I 374–377
  - selecting improved polymerase activity II 377–381
- RNA polymerases 156, 193, 346, 353, 363, 364, 373, 379, 491, 787
- RNA polymerization 351, 352, 360–363, 366, 370, 371, 376, 380, 389, 490
- RNA postsynthetically, spin labeling of 829, 831
- RNA recognition motifs (RRMs) 187
- RNA recombinases 433, 449–450
- RNA recombination 419, 420
  - Azoarcus* RNA fragments 425–427
  - Azoarcus* group I intron 421–422
  - autocatalysis 428
  - chemistry 420
  - cooperative self assembly 429–430
  - crystal structure 422
  - game theoretic treatment 430–434
  - mechanism 422–423
  - prebiotic chemistry model 423–425

- RNA repair 344, 443, 446–449  
 RNA replicase 360–364, 380, 381, 396, 402, 420  
 RNA replicator  
   reaction conditions 366–367  
   sequence space 364–366  
   strand separation problem 367  
 RNA self-replication 362, 364  
 RNA sequences 91, 229, 232, 292, 360, 364–366, 378, 488, 489, 505, 508, 519, 523, 524, 537, 538, 546, 550, 551, 561, 565, 745, 770  
 RNA strands 239, 360, 361, 403, 433, 454, 767, 832, 834  
 RNA structure type 8, 23, 25, 64, 99, 177, 179, 229–233, 235, 250, 284, 367, 380, 450, 463, 557, 770, 866, 867, 869, 871  
 RNA synthesis 332, 377–379, 488, 489, 828–829  
 RNA template 26, 30, 351, 362, 367, 371, 377, 378, 565, 798  
 RNA transcriptomic SELEX 535–537  
 RNA-DNA duplexes 582  
 RNA-ligand complex 868, 870  
 RNA-RNA ligation 420  
 RNA/DNA chimeric substrate 688  
 RNAComposer 866  
 RNase P ribozyme 227  
   A248/nt-1 interaction 251–253  
   active site architecture 250–251  
   antibiotic target 254–258  
   architectural principles 233–235  
   EGS technology 259–261  
   guide sequence (GS) concept 258–259  
   holoenzyme 257–258  
   P protein 258  
   P15 module 253–254  
   single protein subunit 233  
   structure and evolution 229–233  
   substrate interaction 235–247  
   two-metal ion mechanism 247–250  
   variations, idiosyncrasies 233–235  
 RNase P ribozyme  
   structure and evolution 229–233  
 rolling cycle amplification (RCA) 709, 710, 727  
 root-mean square fluctuations (RMSF)  
   analysis 478  
 R5P 336–340  
 R18 polymerase ribozyme 366, 369, 374, 375  
 R2 protein 31–33
- S**
- Sarcin-Ricin loop (SRL) 197, 199, 201, 202, 206, 211  
 satellite RNAs 25, 27–30, 283, 284, 303, 304, 439, 868  
 scissile phosphate 3, 12, 16, 60–69, 72–81, 101, 105, 108, 154, 174, 176, 185, 187, 422, 473, 478, 488, 692, 742–748, 755, 759, 767, 770–771  
 scissile phosphodiester 108, 109, 244, 248, 252, 767–770, 800  
 screening catalyst-coding gene libraries  
   double emulsions 727–728  
   microbead-display 728–729  
 secondINTRONIC HHR 312–315  
 selected ribozyme sequence 479  
 SELEX 722, 724  
   cycle 492  
   polymerization 595–602  
 self-alkylation reaction 551, 553  
 self-aminoacylation 520, 522–524  
 self-cleaving ribozymes 23, 25  
   biological roles 42–43  
   classes 24  
   DNA intermediate 29–30  
   glucosamine-6-phosphate 41–42  
   hepatitisδ virus RNA 29  
   inretrotransposition 25  
   mRNA biogenesis 41  
   synthetic biology 43  
   transposable elements 30–40  
   viroid like satellite RNAs 28

- self-cleaving ribozymes (*contd.*)
- viroids 25–28
  - self-modifying ribozymes
    - in vitro compartmentalization 725–732
    - self-replication 132, 350, 359, 361, 362, 364, 378, 380, 381, 389, 396, 402, 420, 453
    - self-splicing hairpin ribozymes 452–454
    - self-splicing intron (SSI) 5, 17, 39, 72, 248, 283, 293–295, 331, 359, 362, 508, 721, 754
    - self-splicing ribozymes
      - group II introns (GIIi) 143–145
    - serendipity 283–285
    - 70S formation 197
    - Shine–Dalgarno sequence 509, 758
    - short internally deleted elements (SIDEs) 34
    - short single-stranded DNA (ssDNA) 149, 150, 548, 703, 709, 710
    - signal recognition particle (SRP) 770
    - single molecule Förster resonance energy transfer (smFRET) 212
    - single-frequency technique for refocusing dipolar couplings (SIFTER) 824, 825
    - single wavelength anomalous diffraction (SAD) 772
    - 30S initiation complex (30SIC) 196, 199
    - 70S initiation complex (70SIC) 196, 197, 199
    - site directed spin labeling
      - labeling long RNAs 832–834
      - nitroxides 837–838
      - non-covalent labeling 834–837
      - postsynthetic labeling 829–832
      - RNA synthesis 828–829
    - small angle X-ray scattering (SAXS) 98, 125, 470, 772, 817
    - small long terminal repeat
      - retrotransposons (SMARTs) 40
    - small nuclear ribonuclear protein particles (snRNPs) 171
    - small nuclear RNA (snRNA) 143, 171–188, 312, 317, 564, 721
    - small ribosomal subunit (SSU) 194, 309, 509, 513
    - small self-cleaving ribozymes
      - discontinuous HHR 307–310
      - from retrotransposition to
        - domestication 303–304
        - hammerhead ribozyme 304–307
        - Hepatitis D virus ribozymes 318–322
        - intronic HDV-like ribozyme 320–322
        - intronic HHR 310–315, 318
      - small subunit (SSU) rRNA 119
      - 817 small-molecule coenzyme 82
      - smaRt-SELEX approach 537
      - $S_N2$ -like reaction 754, 755, 760, 767, 772, 777
      - snRNPs 170–171, 179
      - Sonogashira C-C cross coupling 829
      - specificity domain (S-domain) 229
      - S phase cyclin A-associated protein in the endoplasmic reticulum (SCAPER) 316, 317
      - splice donor (SD) 668, 672
      - spliceosomal
        - cycle 171–172, 188
        - group II active sites 187–188
        - snRNA structures 173–174
        - structural studies 177
        - spliceosomal RNP 187–188
        - spliceosomal splicing 132–134
        - spliceosome
          - activation 182
          - active site 176
          - assembly pathway 172–173
          - biochemical characterization 179
          - disassembly 187
          - post-catalytic 185, 187
          - snRNPs 170–171
        - splicing 170
          - assays 119
          - chemistry of 173–176
        - S/R complex 466, 470–474, 480
        - ssNMR 1, 3
        - stem-loop I (SLI) 464, 474, 475, 476, 479, 480, 558, 667, 695, 802
        - substrate 464–474
        - SLI/SLV complex 470, 471, 476, 480

- stem-loop V (SLV) 464, 467, 468, 470, 472–473, 476–481
- stochastic corrector model 399–401
- sub-megalaton enzymes 145
- substrate/ribozyme (*S/R*) complex 466, 470
- symmetric rolling circle replication 28
- synthetic oligonucleotides 488, 489, 642, 768
- t**
- $\alpha$ TAR antisense domain 671–672
- target DNA-primed reverse transcription (TPRT) 32, 33, 35, 39, 149
- target-primed reverse transcription 33
- target-site duplications (TSDs) 36, 39, 40
- tautomerization 202, 394, 744
- TcdC 696
- telomerase reverse transcriptases (TERTs) 39
- temperature replica exchange molecular dynamics (T-REMD) 477, 478, 479, 480, 481
- template-based modeling 862–866
- template-free modeling 862, 866–867
- terminal-repeat retrotransposons in miniature (TRIMs) 40
- tethered self-tagging (TST) 379
- tetracycline regulated promoters 136
- Tetrahymena* group I intron 333, 346, 362, 368, 433, 845
- Tetrahymena* ribozyme 421, 424, 425, 439, 578, 762
- tetramethylrhodamine (TMR) 699
- thio-modified phosphoramidites 832
- thio-modified RNA bases 832
- thiophilic metals 690–692
- thymine dimer repair 622–625
- Toehold-mediated strand displacement 637, 639, 643, 647
- trans*-activation response element (TAR) domain 667, 669, 670
- transfer RNA (tRNA)
- for in vitro selection 535–537
  - maturity 331
  - from RNA pool 535
- substrate sequence 526
- tRNA/ribosome pairs 530–532
- transition state theory 4–5
- translation cycle 196
- 30PIC formation 197–198
  - 30SIC formation 199
  - 70SIC formation 199
  - elongation 199–208
  - initiation 196–199
  - mRNA 198–199
  - recycling 211–213
  - termination 208–211
- transposable elements (TEs)
- copy and paste mechanism 30
  - cut and paste mechanism 30
  - hammerhead ribozymes 35–40
  - non-LTR retrotransposons lineages 34–35
  - R2 elements 30–34
  - retrozymes 40
- transposons 30, 40
- TRAP 444, 445
- tri-snRNP 172, 177–179, 182, 187
- tRid 535, 536, 538
- trigger ionization 744
- trimetaphosphate (TMP) 332–335
- twin ribozymes
- for RNA repair and recombination 446–449
  - mediated RNA recombination 448–449
- twister ribozymes 59, 66–69, 80, 287, 289, 292, 388, 748, 774
- natural ribozymes 773–774
- twister RNA structure 288, 289
- twister sister (TS) ribozymes 74–76, 287
- case studies 869, 870
  - natural ribozymes 776–777
- two-metal ion mechanism 247–250, 762
- u**
- 3' untranslated regions (UTRs) 31, 92, 292, 293, 307, 510
- 5' untranslated regions (5' UTRs) 31, 92, 285, 286

**V**

- vanadate ion 767, 779  
 Varkud satellite (VS) 9, 25, 57, 61–66,  
     284, 380, 392, 463, 664, 753,  
     869  
     case studies 869  
     natural ribozymes 770–771  
 viroids 25–29, 40, 58, 283, 284, 303, 304,  
     318  
 viroid like satellite RNAs 25–28  
 viruses  
     dengue 639–640  
     serotypes 639–640

**W**

- water-in-oil (W/O) emulsion 374, 728  
 Watson–Crick (WC) base pairs 7, 69,  
     235, 431, 432, 442, 464, 467, 530,  
     767

- Watson–Crick base pairing 204, 229,  
     239, 260, 266, 333, 365, 368, 369,  
     376, 381, 507, 558, 587, 594, 634

Watson–Crick complementarity 434

Watson–Crick like geometry 202

**X**

- X-ray crystallization 687  
 X-ray crystallography 3, 79, 96, 99, 117,  
     119, 122, 123, 125, 127, 134, 138,  
     372, 476, 563, 741, 762, 767, 817  
 XNA 495, 496, 602, 622  
 XNAzymes 495, 496

**Y**

- ytterbium 765

**Z**

- Z-anchor 152–154







